This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (119)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Endocrine Diseases  • Diabetes Mellitus  • Alert me on articles by topic  Social Bookmarking   What's this?

Scientific Review

Dawn E. DeWitt, MD, MSc; Irl B. Hirsch, MD

JAMA. 2003;289:2254-2264.

Context  Newer insulin therapies, including the concept of physiologic basal-prandial insulin and the availability of insulin analogues, are changing clinical diabetes care. The key to effective insulin therapy is an understanding of principles that, when implemented, can result in improved diabetes control.

Objective  To systematically review the literature regarding insulin use in patients with type 1 and type 2 diabetes mellitus (DM).

Data Sources  A MEDLINE search was performed to identify all English-language articles of randomized controlled trials involving insulin use in adults with type 1 or type 2 DM from January 1, 1980, to January 8, 2003. Bibliographies and experts were used to identify additional studies.

Study Selection and Data Extraction  Studies were included (199 for type 1 DM and 144 for type 2 DM, and 38 from other sources) if they involved human insulins or insulin analogues, were at least 4 weeks long with at least 10 patients in each group, and glycemic control and hypoglycemia were reported. Studies of insulin-oral combination were similarly selected.

Data Synthesis  Twenty-eight studies for type 1 DM, 18 for type 2 DM, and 48 for insulin-oral combination met the selection criteria. In patients with type 1 DM, physiologic replacement, with bedtime basal insulin and a mealtime rapid-acting insulin analogue, results in fewer episodes of hypoglycemia than conventional regimens. Rapid-acting insulin analogues are preferred over regular insulin in patients with type 1 DM since they improve HbA_1C and reduce episodes of hypoglycemia. In patients with type 2 DM, adding bedtime neutral protamine Hagedorn (isophane) insulin to oral therapy significantly improves glycemic control, especially when started early in the course of disease. Bedtime use of insulin glargine results in fewer episodes of nighttime hypoglycemia than neutral protamine Hagedorn regimens. For patients with more severe insulin deficiency, a physiologic insulin regimen should allow lower glycemic targets in the majority of patients. Adverse events associated with insulin therapy include hypoglycemia, weight gain, and worsening diabetic retinopathy if hemoglobin A_1C levels decrease rapidly.

Conclusions  Many options for insulin therapy are now available. Physiologic insulin therapy with insulin analogues is now relatively simple to use and is associated with fewer episodes of hypoglycemia.

Author Affiliations: Division of General Internal Medicine, Department of Medicine, University of Washington (Dr DeWitt); and Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, University of Washington, and Diabetes Care Center, University of Washington Medical Center (Dr Hirsch), Seattle.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Using New Insulin Strategies in the Outpatient Treatment of Diabetes: Clinical Applications
Dawn E. DeWitt and David C. Dugdale
JAMA. 2003;289(17):2265-2269.
ABSTRACT | FULL TEXT  

Insulin
Sharon Parmet, Cassio Lynm, and Richard M. Glass
JAMA. 2003;289(17):2314.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Implications of Postprandial Glucose and Weight Control in People With Type 2 Diabetes: Understanding and implementing the International Diabetes Federation guidelines
Gallwitz
Diabetes Care 2009;32:S322-S325.
FULL TEXT  

The Effect of Disability Insurance on Health Investment: Evidence from the Veterans Benefits Administration's Disability Compensation Program
Singleton
J. Human Resources 2009;44:998-1022.
ABSTRACT  

Case Series: Premixed Insulin Dosing in Actual Practice: Two-Thirds in AM, One-Third in PM, or Half and Half?
Bhargava et al.
Clin. Diabetes 2009;27:91-95.
FULL TEXT  

Hypoglycemia with Intensive Insulin Therapy: A Systematic Review and Meta-Analyses of Randomized Trials of Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections
Fatourechi et al.
J. Clin. Endocrinol. Metab. 2009;94:729-740.
ABSTRACT | FULL TEXT  

Sliding Scale Insulin--Time to Stop Sliding
Hirsch
JAMA 2009;301:213-214.
FULL TEXT  

Standards of Medical Care in Diabetes--2009
American Diabetes Association
Diabetes Care 2009;32:S13-S61.
FULL TEXT  

Factors Affecting Use of Insulin Pens by Patients With Type 2 Diabetes
Rubin and Peyrot
Diabetes Care 2008;31:430-432.
ABSTRACT | FULL TEXT  

Diabetes Treatment, Part 3: Insulin and Incretins
Fowler
Clin. Diabetes 2008;26:35-39.
FULL TEXT  

Standards of Medical Care in Diabetes--2008
American Diabetes Association
Diabetes Care 2008;31:S12-S54.
FULL TEXT  

Development and Validation of a New Measure to Evaluate Psychological Resistance to Insulin Treatment
Petrak et al.
Diabetes Care 2007;30:2199-2204.
ABSTRACT | FULL TEXT  

Insulin Therapy for Maximal Glycemic Control in Type 2 Diabetes Mellitus
Spellman
JAOA: Journal of the American Osteopathic Association 2007;107:260-269.
ABSTRACT | FULL TEXT  

Use of Insulin Pump Therapy in the Pediatric Age-Group: Consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes
Phillip et al.
Diabetes Care 2007;30:1653-1662.
FULL TEXT  

Inhaled Insulin for Diabetes Mellitus
McMahon and Arky
NEJM 2007;356:497-502.
FULL TEXT  

Standards of Medical Care in Diabetes--2007
American Diabetes Association
Diabetes Care 2007;30:S4-S41.
FULL TEXT  

The Meaning of Autoantibody Titers, Exercise, and Alcohol in a Thin 65-Year-Old Man Hospitalized for Cholangitis and Coincidental New Diabetes
Babington and DeWitt
Clin. Diabetes 2006;24:185-186.
FULL TEXT  

The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes
Kilpatrick et al.
Diabetes Care 2006;29:1486-1490.
ABSTRACT | FULL TEXT  

Counterpoint: Are Insulin Pumps Underutilized in Type 1 Diabetes? No.
Schade and Valentine
Diabetes Care 2006;29:1453-1455.
FULL TEXT  

Physiologic insulin replacement in type 2 diabetes: optimizing postprandial glucose control.
Robertson
The Diabetes Educator 2006;32:423-432.
ABSTRACT | FULL TEXT  

Use of Continuous Subcutaneous Insulin Infusion Pump in Patients With Type 2 Diabetes Mellitus
Nielsen et al.
The Diabetes Educator 2005;31:843-848.
ABSTRACT | FULL TEXT  

Resistance to Insulin Therapy Among Patients and Providers: Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study
Peyrot et al.
Diabetes Care 2005;28:2673-2679.
ABSTRACT | FULL TEXT  

70/30 Insulin Algorithm Versus Sliding Scale Insulin
Schoeffler et al.
The Annals of Pharmacotherapy 2005;39:1606-1609.
ABSTRACT | FULL TEXT  

Discordant Trends in Microvascular Complications in Adolescents With Type 1 Diabetes From 1990 to 2002
Mohsin et al.
Diabetes Care 2005;28:1974-1980.
ABSTRACT | FULL TEXT  

Insulin Analogues
Hirsch
NEJM 2005;352:174-183.
FULL TEXT  

Hyperglycemia in the Hospital
Thompson et al.
Diabetes Spectr. 2005;18:20-27.
ABSTRACT | FULL TEXT  

Were We Wrong About Insulin and Acute Myocardial Infarction?
Hirsch
DOC News 2004;1:4-5.
FULL TEXT  

Hospital Management of Hyperglycemia
Campbell and Braithwaite
Clin. Diabetes 2004;22:81-88.
FULL TEXT  

Review of Insulin Therapy
Daugherty
Journal of Pharmacy Practice 2004;17:10-19.
ABSTRACT  

Insulin Delivery Devices
Stewart et al.
Journal of Pharmacy Practice 2004;17:20-28.
ABSTRACT  

Similar A1C Outcomes in Type 1 Diabetic Patients Undergoing Intensive Diabetes Management With Preprandial Rapid-Acting Insulin and Either CSII or Glargine
Harmel and Mathur
Diabetes Care 2004;27:272-273.
FULL TEXT  

OTHER ARTICLES NOTED (25 Apr 2003 to 18 Jul 2003)
Evid. Based Nurs. 2003;6:e1-12.
FULL TEXT  

The Rationale and Management of Hyperglycemia for In-Patients with Cardiovascular Disease: Time for Change
Trence et al.
J. Clin. Endocrinol. Metab. 2003;88:2430-2437.
ABSTRACT | FULL TEXT